The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Another superb RNS this morning, this one to kindly let us know that we will incur additional revenues of up to $310m. And it’s not Covid related. Looking at our market cap this SP is now significantly undervalued imo.
“I look forward to further updating the market as we go through the next stages of manufacturing scale-up, clinical validation, regulatory approval and product launch”
The next steps before sales are clear... clinical validation (Proof our product works) is what we have been waiting for but just remember we already know it works... Big Al told us so ;-)
Well done to all the holders and good riddance to the bed wetters...
“I look forward to further updating the market on progress in our ground-breaking programmes with AffyXell in due course, and on progress with our COVID-19 diagnostics programmes shortly."
The fundamentals of this stock hasn’t changed. Investors need to sit tight. Many won’t have the benefit of an informative bb like this and will panic on the drops. I suspect if this does drop below the placing price of £1.20 then many stop losses will be triggered... the demand for this stock is there people are looking for your shares
https://www.sharesmagazine.co.uk/shares/share/AVCT/trades
Not sure if anyone else noticed the 16.35 trade : a buy of ONE share at £1.36
We know what that means don’t we ;-)
DOH85 the “leaky ship“ was PrimaryBid who ran the placing - they are well known for it. Nothing suggests Avacta have a leak we haven’t seen anything suspicious before any RNS... that why I believe it could be a surprise when it hits
These tests are just interim tests until ours hits the market... a market which is a whole lot bigger than the UK market... of which we will have a large share of... ours are going to be available when they are ready, and in the meantime inferior products will also hit the market. As long as they are inferior what is the problem.
Morning all. Why is everyone in a mad panic? I see this mornings news as good news - we now have a new benchmark... a 90 min SWAB test which is vastly inferior to ours! Our share price should be going up not down. Absolutely nothing has changed all the evidence suggests we are still on track...
Excellent RNS from Avacta yesterday:
AffyXell, a "next-generation cell and gene therapy" company (being a JV between South Korea's Daewoong Pharma (55%) and AVCT (45%)), is now developing mesenchymal stem cell ('MSC') treatments that incorporate Affimers for Covid-19.
How this didn’t climb towards £3 on the back of this is quite astonishing. With more positive news expected this now appears to be a massively undervalued stock and a very strong buy imo.
I LOOK FORWARD to further updating the market on progress in our ground-breaking programmes with AffyXell in due course, AND on progress with our COVID-19 diagnostics programmes shortly."
Confirmation the LFT is on track.... what a superb RNS. Should increase 5-10% today ready for the big 1